FDAnews Drug Daily Bulletin

IDENIX ANNOUNCES COMPLETION OF STOCK SALE WORTH AROUND $23M

Nov. 29, 2005
A A

Idenix Pharmaceuticals Inc. reports that the underwriters of its public offering exercised in full their over-allotment option and completed the purchase at the public offering price of $20.61 per share of 1.1 million additional shares of Idenix common stock from certain stockholders of the company. The Cambridge company did not receive any proceeds from the over-allotment option exercise or sale of the shares by selling stockholders.

Boston Mass High Tech (http://www.masshightech.com/displayarticledetail.asp?Art_ID=70390)